Author: Kumar, Rahul; Lee, Michael H.; Mickael, Claudia; Kassa, Biruk; Pasha, Qadar; Tuder, Rubin; Graham, Brian
Title: Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19 Cord-id: oea187i2 Document date: 2020_12_7
ID: oea187i2
Snippet: Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) gains entry into the lung epithelial cells by binding to the surface protein angiotensin-converting enzyme 2. Severe SARS-CoV-2 infection, also known as coronavirus disease 2019 (COVID-19), can lead to death due to acute respiratory distress syndrome mediated by inflammatory immune cells and cytokines. In this review, we discuss the molecular and biochemical bases of the interaction between SARS-CoV-2 and human cells, and in doing so w
Document: Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) gains entry into the lung epithelial cells by binding to the surface protein angiotensin-converting enzyme 2. Severe SARS-CoV-2 infection, also known as coronavirus disease 2019 (COVID-19), can lead to death due to acute respiratory distress syndrome mediated by inflammatory immune cells and cytokines. In this review, we discuss the molecular and biochemical bases of the interaction between SARS-CoV-2 and human cells, and in doing so we highlight knowledge gaps currently precluding development of new effective therapies. In particular, discovery of novel treatment targets in COVID-19 will start from understanding pathologic changes based on a large number of autopsy lung tissue samples. Pathogenetic roles of potential molecular targets identified in human lung tissues must be validated in established animal models. Overall, this stepwise approach will enable appropriate selection of candidate therapeutic modalities targeting SARS-CoV2 and the host inflammatory response.
Search related documents:
Co phrase search for related documents- acute respiratory distress syndrome and adaptive cell response: 1, 2
- acute respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acute respiratory distress syndrome and adaptive immune response dysregulate innate: 1
- acute respiratory distress syndrome and adjunctive therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- adaptive immune response and lopinavir ritonavir: 1
- adaptive immune response and lung damage: 1, 2, 3, 4, 5, 6
- adaptive immune response and lung disease: 1, 2, 3, 4, 5, 6
- adaptive immune response and lung epithelial cell: 1
- adaptive immune response and lung function: 1, 2, 3, 4
- adaptive immune response and lung inflammatory response: 1
- adaptive immune response and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9
- adaptive immune response and lung pathology: 1, 2, 3, 4
- adaptive immune response and lung repair: 1
- adaptive immune response and lung tissue: 1, 2, 3, 4, 5, 6, 7
- adaptive immune response and lymph node: 1, 2, 3, 4, 5, 6
- adaptive immune response and lymph spleen: 1, 2, 3
- adaptive immune response and lymphocyte neutrophil: 1
- adaptive immune response and lymphocyte population: 1
- adaptive immune response and macrophage inflammatory: 1
Co phrase search for related documents, hyperlinks ordered by date